DGAP-News: Raptor Pharmaceutical Corp. Expands Senior Management
(firmenpresse) - Raptor Pharmaceutical Corp.
10.09.2012 22:05
---------------------------------------------------------------------------
NOVATO, Calif., 2012-09-10 22:05 CEST (GLOBE NEWSWIRE) --
Raptor Pharmaceutical Corp. ('Raptor' or the 'Company') (Nasdaq:RPTP), today
announced the appointment of Georgia Erbez, as Chief Financial Officer of
Raptor, and Julie Anne Smith, as Executive Vice President, Strategy, and Chief
Operating Officer.
Ms. Erbez will be responsible for directing Raptor's global financial strategy
and organization and providing leadership in defining, communicating, and
executing corporate and financial strategic initiatives. Ms. Smith will be
responsible for directing Raptor's commercial, manufacturing, and program
management organizations, and providing leadership in corporate and strategic
development initiatives. Both Ms. Erbez and Ms. Smith will report to
Christopher M. Starr, Ph.D, Chief Executive Officer of Raptor.
'We are thrilled to add Georgia and Julie to Raptor's executive management
team,' stated Christopher Starr, Raptor's CEO. 'Their combined skills and
experience in strategic finance, orphan drug development and commercialization
will greatly enhance our execution capabilities and ability to realize our full
growth potential as we anticipate the first approval of our drug for treating
cystinosis next year and continue to advance our development programs.'
Ms. Erbez has over 20 years of experience in investment banking focused on
providing comprehensive financial and strategic advisory services to life
science companies. Most recently, Ms. Erbez, as the founder and managing
director of Beal Advisors, a boutique investment bank, has provided advisory
and capital raising services to emerging growth companies. Ms. Erbez previously
worked at Jefferies&Co., SG Cowen, Hambrecht&Quist and Alex. Brown&Sons.
Ms. Erbez has participated in over 70 financing and merger transactions in the
health care industry valued at over $7.0 billion. Kim Tsuchimoto, who has
played a critical role in Raptor's development, will continue in a financial
and administrative capacity as Vice President Finance.
Ms. Smith has nearly 20 years of experience in biotech with the preponderance
spent in orphan drug development and commercial product opportunities. She has
served in executive management of both private and public biotech firms, most
recently, as Chief Commercial Officer of Enobia Pharma, Inc., an orphan product
clinical stage company acquired by Alexion (Nasdaq:ALXN). Prior to that, she
served as Vice President, Commercial, for Jazz Pharmaceuticals, and Vice
President Product Development and Global Marketing for Genzyme where she led
the worldwide commercialization and planning for Myozyme(r), an infused enzyme
therapy for ultra-orphan genetic disease.
About Raptor Pharmaceutical Corp.
Raptor Pharmaceutical Corp. (Nasdaq:RPTP) ('Raptor') seeks to research,
produce, and deliver medicines that improve life for patients with severe, rare
disorders. Raptor currently has product candidates in clinical development
designed to potentially treat nephropathic cystinosis, Non-alcoholic
Steatohepatitis ('NASH'), Huntington's Disease ('HD'), aldehyde dehydrogenase
deficiency ('ALDH2'), and thrombotic disorder.
Raptor's preclinical programs are based upon bioengineered novel drug
candidates and drug-targeting platforms derived from the human
receptor-associated protein and related proteins that are designed to target
cancer and infectious diseases.
For additional information, please visit www.raptorpharma.com.
The Raptor Pharmaceutical Corp. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=7180
FORWARD-LOOKING STATEMENTS
This document contains forward-looking statements as that term is defined in
the Private Securities Litigation Reform Act of 1995. These statements relate
to future events or our future results of operation or future financial
performance. These statements are only predictions and involve known and
unknown risks, uncertainties and other factors, which may cause the Company's
actual results to be materially different from these forward-looking
statements. Factors which may significantly change or prevent the Company's
forward looking statements from fruition include: that Raptor may be
unsuccessful in developing any products or acquiring products; that Raptor's
technology may not be validated as it progresses further and its methods may
not be accepted by the scientific community; that Raptor is unable to retain or
attract key employees whose knowledge is essential to the development of its
products; that the addition of Ms. Erbez and Ms. Smith to Raptor's management
team will enhance Raptor's management team; that unforeseen scientific
difficulties develop with the Company's process; that Raptor's patents are not
sufficient to protect essential aspects of its technology; that competitors may
invent better technology; that Raptor's products may not work as well as hoped
or worse, that the Company's products may harm recipients; and that Raptor may
not be able to raise sufficient funds for development or working capital. As
well, Raptor's products may never develop into useful products and even if they
do, they may not be approved for sale to the public. Raptor cautions readers
not to place undue reliance on any such forward-looking statements, which speak
only as of the date they were made. Certain of these risks, uncertainties, and
other factors are described in greater detail in the Company's filings from
time to time with the Securities and Exchange Commission (the 'SEC'), which
Raptor strongly urges you to read and consider, including: Raptor's annual
report on Form 10-K and Amendment No. 1 to its Annual Report on Form 10-K/A
filed with the SEC on November 14, 2011 and December 19, 2011, respectively;
and Raptor's quarterly report on Form 10-Q filed with the SEC on July 10, 2012,
which are available free of charge on the SEC's web site at http://www.sec.gov.
Subsequent written and oral forward-looking statements attributable to Raptor
or to persons acting on its behalf are expressly qualified in their entirety by
the cautionary statements set forth in Raptor's reports filed with the SEC.
Raptor expressly disclaims any intent or obligation to update any
forward-looking statements.
CONTACT: Trout Group (investors)
Lauren Glaser
(646) 378-2972
lglaser(at)troutgroup.com
EVC Group (media)
Janine McCargo
(646) 688-0425
jmccargo(at)evcgroup.com
News Source: NASDAQ OMX
10.09.2012 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Raptor Pharmaceutical Corp.
United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US75382F1066
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 10.09.2012 - 22:05 Uhr
Sprache: Deutsch
News-ID 182018
Anzahl Zeichen: 0
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 175 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Raptor Pharmaceutical Corp. Expands Senior Management"
steht unter der journalistisch-redaktionellen Verantwortung von
Raptor Pharmaceutical Corp. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
